TITLE

Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia

AUTHOR(S)
Horvitz-Lennon, Marcela; Donohue, Julie M.; Domino, Marisa E.; Normand, Sharon-Lise T.
PUB. DATE
May 2009
SOURCE
Health Affairs;May/Jun2009, Vol. 28 Issue 3, p701
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The slow spread of treatments supported by empirical evidence and the rapid diffusion of treatments lacking such support play major roles in the lower quality of mental health care received by people with severe mental illnesses compared with the care of less severely ill people. Further, the rapid spread of treatments that are of low cost-effectiveness limits the system's ability to provide the full gamut of high-value treatments available to treat this vulnerable population. Using the case of schizophrenia, we review the context in which these paradoxical patterns of diffusion have occurred, and we propose policy solutions.
ACCESSION #
39761770

 

Related Articles

  • State Variations In The Out-Of-Pocket Spending Burden For Outpatient Mental Health Treatment. Zuvekas, Samuel H.; Meyerhoefer, Chad D. // Health Affairs;May/Jun2009, Vol. 28 Issue 3, p713 

    We examine the potential of mental health/substance abuse (MH/SA) parity laws to reduce the out-of-pocket spending burden for outpatient treatment at the state level by exploring cross-state variations and their causes, as well as the provisions of MH/SA parity laws. We find modest (yet...

  • The clinical and cost effectiveness of group art therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness analysis. Uttley, Lesley; Stevenson, Matt; Scope, Alison; Rawdin, Andrew; Sutton, Anthea // BMC Psychiatry;9/10/2015, Vol. 15 Issue 1, p1 

    Background: The majority of mental health problems are non-psychotic (e.g., depression, anxiety, and phobias). For some people, art therapy may be a more acceptable alternative form of psychological therapy than standard forms of treatment, such as talking therapies. This study was part of a...

  • Treatment of Long-Term Psychiatric Disorders in the Managed Care Environment: An Observational Longitudinal Study. Dickey, B.; Normand, S-L.T.; Norton, E.C.; Azeni, H.; Fisher, W. // Clinical Drug Investigation;1998, Vol. 15 Issue 4, p303 

    In the USA, mental health expenditures have been rising at a rate that exceeds other medical expenditures. To control these costs, insurance companies and governmental agencies responsible for health benefit plans have turned to managed care companies who review utilisation of services and who...

  • Improving Mental Health Treatments Through Comparative Effectiveness Research. Wang, Philip S.; Ulbricht, Christine M.; Schoenbaum, Michael // Health Affairs;May/Jun2009, Vol. 28 Issue 3, p783 

    There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental...

  • PMS reviews ignore quality for average care.  // GP: General Practitioner;2/22/2008, p21 

    The author reflects on the relationship between the quality of services and the income of personal medical services (PMS) partners in Great Britain. He states that reducing PMS partners's income to pre-new-general medical services contract (GMS) levels is not the best way to ensure quality...

  • Mental illness bill for England tops £77bn.  // GP: General Practitioner;6/9/2003, p15 

    Mental illness costs England £ billion a year — twice as much as previously thought, according to research from the Sainsbury Centre for Mental Health (SCMH), as of June 2003. As well as including medical and social care costs, researchers calculated and included the cost of reduced...

  • Long-acting risperidone warranted in chronic schizophrenia.  // PharmacoEconomics & Outcomes News;7/16/2005, Issue 482, p6 

    Discusses research being done on the treatment of chronic schizophrenia with long-acting risperidone. Reference to a study by J. C. Locklear et al, presented at the American Psychiatric Association 2005 Annual Meeting; Comparison to currently available treatments; Savings in direct medical...

  • Long-acting risperidone most economical choice in schizophrenia.  // PharmacoEconomics & Outcomes News;5/7/2005, Issue 477, p6 

    Discusses research being done on the use of a decision-analysis model to determine the cost-effectiveness of long-acting risperidone in the treatment of schizophrenia in the U.S. Reference to a study by N. C. Edwards and colleagues, published in a 2005 issue of "PharmacoEconomics" journal;...

  • Medically unexplained symptoms. Webb, Tim // Therapy Today;Apr2010, Vol. 21 Issue 3, p10 

    The author discusses the importance of addressing medically unexplained symptoms (MUS) to treat a particular psychological illness as well as reduce health services costs. He states that MUS are signs of physical malfunctions that physicians failed to identify. The author adds that these...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics